Literature DB >> 6519174

Mesulergine, a selective serotonin-2 ligand in the rat cortex, does not label these receptors in porcine and human cortex: evidence for species differences in brain serotonin-2 receptors.

A Pazos, D Hoyer, J M Palacios.   

Abstract

The kinetic and pharmacological characteristics of the binding of [3H]ketanserin and [3H]mesulergine to frontal cortical brain membranes from rat, pig and human were studied. In the 3 species [3H]ketanserin labeled sites with the characteristics of the 5-HT2 receptors previously described in the rat. In contrast, [3H]mesulergine labeled 5-HT2 receptors in rat, but not in pig and human cortices. The characteristics of the sites labeled by [3H]mesulergine in pig cortex were similar to those of sites in the choroid plexus of rats, pigs and humans. While several reputed 5-HT2 ligands presented a similar affinity for the [3H]ketanserin binding sites in the 3 species, other such ligands, e.g. mesulergine, methysergide, cinanserin and LSD which displaced these sites with high affinity in rat brain, had lower affinities in pig and human brain. These results indicate that 5-HT2 receptors show different pharmacological profiles in different species. Caution should thus be exerted in extrapolating data from laboratory animals to humans.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6519174     DOI: 10.1016/0014-2999(84)90056-6

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  31 in total

1.  "5-HT1R" or 5-HT1D sites? Evidence for 5-HT1D binding sites in rabbit brain.

Authors:  D Hoyer; H Lery; C Waeber; A T Bruinvels; J Nozulak; J M Palacios
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-09       Impact factor: 3.000

2.  Molecular structural basis of ligand selectivity for 5-HT2 versus 5-HT1C cortical receptors.

Authors:  P A Pierce; J Y Kim; S J Peroutka
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-07       Impact factor: 3.000

3.  Brain gamma-glutamyltranspeptidase: characteristics, development and thyroid hormone dependency of the enzyme in isolated microvessels and neuronal/glial cell plasma membranes.

Authors:  S J Hemmings; K B Storey
Journal:  Mol Cell Biochem       Date:  1999-12       Impact factor: 3.396

Review 4.  A short history of the 5-HT2C receptor: from the choroid plexus to depression, obesity and addiction treatment.

Authors:  Jose M Palacios; Angel Pazos; Daniel Hoyer
Journal:  Psychopharmacology (Berl)       Date:  2017-03-07       Impact factor: 4.530

5.  Central and peripheral hypotensive activity of urapidil and its M1 and M2 metabolites in the cat.

Authors:  H Boss; R Boer; K D Beller; K H Sanders
Journal:  Drugs       Date:  1990       Impact factor: 9.546

6.  Is blockade of alpha 1-adrenoceptors favourable in hypotension induced by stimulation of serotonin1A receptors in conscious dogs?

Authors:  K D Beller; R Boer; K H Sanders; B Walter
Journal:  Drugs       Date:  1990       Impact factor: 9.546

7.  [3H]ICS 205-930 labels 5-HT3 recognition sites in membranes of cat and rabbit vagus nerve and superior cervical ganglion.

Authors:  D Hoyer; C Waeber; A Karpf; H Neijt; J M Palacios
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-10       Impact factor: 3.000

8.  L-694,247: a potent 5-HT1D receptor agonist.

Authors:  M S Beer; J A Stanton; Y Bevan; A Heald; A J Reeve; L J Street; V G Matassa; R J Hargreaves; D N Middlemiss
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

9.  Autoradiographic distribution of 5-HT7 receptors in the human brain using [3H]mesulergine: comparison to other mammalian species.

Authors:  Francisco J Martín-Cora; Angel Pazos
Journal:  Br J Pharmacol       Date:  2003-12-01       Impact factor: 8.739

10.  5-HT1C receptor-mediated stimulation of inositol phosphate production in pig choroid plexus. A pharmacological characterization.

Authors:  D Hoyer; C Waeber; P Schoeffter; J M Palacios; A Dravid
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-03       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.